article thumbnail

Short-Term Hormone Therapy for Menopause Won't Harm Women's Brains

Drugs.com

22, 2024 -- Four years of hormone replacement therapy to help women deal with menopausal symptoms causes no harm to the brain, even over the long term, new research shows."In In the present study, approximately 10 years after 48 months of. FRIDAY, Nov.

Therapies 269
article thumbnail

New data showcase promise, growing pains of CAR-T in autoimmune disease

BioPharma Drive: Drug Pricing

One expert described trial results presented at EULAR last week as “unprecedented.” ” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.

Disease 349
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bristol Myers faces FDA delay on cancer cell therapy decision

BioPharma Drive: Drug Pricing

The regulator plans to convene an advisory panel to discuss an expanded indication for Abecma, presenting another hurdle for Bristol Myers and partner 2seventy bio.

Therapies 274
article thumbnail

CG follows big IPO with new results for bladder cancer drug

BioPharma Drive: Drug Pricing

Newly disclosed Phase 3 results presented Friday match findings the biotech disclosed last year, while offering a more comprehensive look at how its drug stacks up to rival therapies.

Drugs 310
article thumbnail

New cell therapy model accelerates cancer treatment development

Drug Target Review

In the rapidly advancing field of cell therapies, Dr Jason Bock has emerged as a leader, known for his innovative approach to optimising the development process. With over 25 years of experience in therapeutics, Bock has played a pivotal role in shaping the future of cell therapies, particularly through his work at CTMC.

article thumbnail

Antisense therapy restores fragile X protein production in human cells

Science Daily: Pharmacology News

An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome.

article thumbnail

Logistics in Focus: Orchestrating the Challenges of Cell Therapy

Conversations in Drug Development Trends

By Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Rare Disease Cell and gene therapies (CGTs) include cutting-edge approaches that offer the hope of a healthier, happier, and better tomorrow for a wide range of patient populations. Below, we discuss some of these challenges in cell therapy trials.